EMA panel backs Bristol Myers' Opdivo-Yervoy for liver cancer
PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...
Le Lézard1h
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...
Le Lézard1h
Merck Receives Positive EU CHMP Opinion for CAPVAXIVEtm (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
Merck , known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the ...
Bristol Myers’ Breyanzi receives positive CHMP opinion in follicular lymphoma
Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...
Merck’s capvaxive receives positive EU CHMP opinion for pneumococcal vaccine
Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...
PharmiWeb3h
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
BioWorld14h
Stereotaxis begins anew with Genesisx launch in EU
Continuing a cascade of positive news for Stereotaxis Inc., the company reported the first order for its petite Genesisx robot in Europe. The system received CE mark in August, but management held off ...
The Pharma Letter1d
EU’s shortages monitoring platform fully operational
The use of the ESMP will become mandatory for MAHs and NCAs as of Sunday, February 2. The platform is a key requirement of ...
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
pharmaphorum2d
EMA abandons X in favour of rival Bluesky
The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...